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Abstract  
Background and Purpose: Fibromyalgia (FM) is a very complex chronic pain condition, characterized 
by widespread musculoskeletal pain, fatigue and numerous other physical and psychological 
symptoms, such as insomnia, morning stiffness, anxiety, depressive disorders and cognitive 
dysfunctions. Most women with FM are also between the ages of 40 to 55 years old, around the pre‐
menopausal and menopausal period. As FM, Menopause (MP) is also associated with physical and 
psychological symptoms, being the end of ovarian activity, whose decline produces a series of trophic, 
metabolic, psychological and sexual consequences, altering the homeostatic balance of the woman. 
The aim of the study was to investigate whether both of the treated syndromes constitute a single 
nosological entity, or two distinct nosological entities and the most accredited hypothesis. 
Methods: Through the analysis of the scientific literature, FM and MP have been analyzed using the 
predicted research objective as a guiding criterion. It was considered useful to analyze the two 
syndromes separately and then to identify a criterion of interdependence between them. The study 
was conducted through the use of some keywords included in the main scientific search databases. 
Results and conclusions: Our research highlight the potential menopausal influence on FM, given that 
the progressive depletion of ovarian activity constitutes the pathophysiological substratum of 
profound hormonal changes, with implications not only in terms of somatic symptoms, but also in 
terms of psychological distress. Furthermore, the lack of scientific evidence about psychological 
correlations between the two syndromes provides an interesting starting point for future research. 
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1. Introduction 
Fibromyalgia (FM), or fibromyalgia syndrome (SFM), is a painful and chronic condition, of 
unknown etiology, characterized by high prevalence in women (97%), and has an overall 
prevalence in the general population between 1% and 6% (Marsico & Cimmino, 2010). Until a 
few decades ago, the diagnosis of FM was carried out in the presence of widespread 
musculoskeletal pain for at least three months, in at least 11 out of the 18 specific sensitive areas 
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of tenderness (tender points). More recently, increased emphasis has been placed on extra skeletal 
symptoms, such as sleep architecture anomalies, fatigability, sleep disorders, problems of 
ideation and / or memory, conditions which contribute to the worsening of the syndrome and 
that influence the quality of life of these patients (Palagini et al., 2016; Wolfe et al., 2010). In 
particular, the main physical symptoms related to FM are: chronic widespread pain, fatigue and 
asthenia, headache and facial pain, chest pain, stiffness, sensation of swelling, paresthesia, 
sensitivity disorders, visual changes, pseudo-allergic symptoms, alterations of balance, 
alterations of the motility of the lower limbs, gastrointestinal disorders and genitourinary 
disorders (American College of Rheumatology, 2010). Furthermore, FM also presents cognitive 
(such as fibro-fog), sexual, emotional and behavioral disorders that interfere with normal daily 
activity (Bazzichi et al., 2013; Carmassi et al., 2017; Conversano et al., 2010, 2019; Dell’Osso et 
al., 2015; Glass et al., 2005; Kuchinad et al., 2007; Mease et al., 2008; Piccinni et al., 2011; Veltri 
et al., 2012). Several studies would show also the involvement of some personality traits with 
FM, such as alexithymia (Conversano et al., 2018; Marchi et al., 2019). 
In fact, patients with FM often fail to satisfy even the ordinary and natural demands of family, 
friends and employers, perceiving their illness as a negative factor with respect to their quality 
of life (Breivik et al., 2006; Dell’Osso et al., 2011). At present, treatment for FM includes 
pharmacological and non-pharmacological therapies, although the effectiveness of both types 
of therapies is still debated (Atzeni et al., 2019; Conversano et al., 2019). An increasing number 
of scientific investigations have examined patients’ experiences of illness and morbidities across 
a variety of chronic conditions, amongst others, diabetes (Marchini et al., 2018; Martino et al., 
2019; Settineri et al., 2019a, 2019b), chronic pain (Catalano et al., 2017), stroke (Orrù et al., 
2019), recidivist post-traumatic stress disorder (Dell’Osso et al., 2014), FM (Lee et al., 2017; 
Verbunt et al., 2008) and MP (Catalano et al., 2018; Martino et al., 2018a, 2018b) using 
comprehensive health-related quality of life questionnaires or other outcomes measures 
provided by the clinical research in order to evaluate specific domains or the burden of the 
diseases, which could be used for syndrome treatment and progression monitoring. 
In 2001, the American Society for Reproductive (Soules et al., 2001) described the various stages 
of reproductive activity and the transition to MP. Each of these phases has its own 
characteristics and presents different individual variations, and are named as follows: 
menopausal transition, perimenopause, and post menopause. For the diagnosis, an amenorrhea 
period of six to twelve months is usually required; however, for some patients this criterion may 
not be adequate, therefore the blood levels of follicle stimulating hormone (FSH) and luteinizing 
hormone (LH) are used to distinguish MP from other forms of secondary amenorrhea (Pescetto 
et al., 2017). About the MP onset, De Bruin and collaborators (2001) state that heredity 
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determines the age variability of the onset of menopause in at least 87% of cases. The climacteric 
symptomatology is varied and related to the variability of the hormonal patterns that are 
determined in each subject, as well as to the reactivity of the different organs and apparatuses 
on which these modifications are reverberated and, finally, to the psychological reactions linked 
to the transition process from the fertile age to that which is no longer fruitful in every woman.  
In particular, the symptoms that are likely to be linked to menopause are: vasomotor symptoms, 
vaginal dryness / dyspareunia, insomnia and mood disorders (Bromberger et al., 2007; Cohen 
et al., 2006; Freeman et al., 2007).  Estrogen deficiency also leads to a reduction in basal 
metabolism with consequent increase in fat mass and accumulation of adipose tissue in the 
abdominal area and alteration of the waist/hip ratio. This change in the distribution of body fat, 
from the gynoid type to the android type, in addition to increasing cardiovascular risk, can 
negatively affect body perception in those women who tend to link their self-esteem to their 
external appearance (Grimaldi et al., 2006).  
Recent studies highlighted how the epidemiological, etiopathogenetic, symptomatic, and 
therapeutic aspects are surprisingly similar between FM and MP; this similarity could lead to the 
hypothesis that FM is part of the climacteric syndrome or vice-versa.  
These two syndromes have been studied scientifically, among others, by Blumel and 
collaborators (2012), who observed that in the etiopathogenesis of both syndromes there are 
almost identical changes in the neurotransmitters of the autonomic nervous system and, 
moreover, that both seem to respond to treatment with estrogens and antidepressants. This 
association could suggest that changes in ovarian hormone levels, starting several years before 
menopause, are related to the onset of FM. Despite this similarity, however, the existence of 
non-climacteric patients with FM, suggests that the hormonal deficit is not the only 
physiopathological mechanism involved in the etiopathogenesis of this syndrome. As a result, 
it is likely that hormonal disorders are involved in the genesis of symptoms in most middle-aged 
women with FM. 
The question that inspired the present work is whether both of the treated syndromes constitute 
a single nosological entity, or of two distinct nosological entities. The answer to this question 
could be very useful, since climacteric syndrome responds to treatments, whereas with FM, 
numerous treatments have been studied, with variable and contrasting results. Furthermore,  
the psychological consequences of the climacteric syndrome could play an important role in 
maintaining or worsening some FM related symptoms, or viceversa. Clarifying the possible 
interdependence between the two syndromes would also help the clinical psychologist in his 
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work, providing him with appropriate tools to manage the complex symptomatic corollary 
characterizing the FM condition. 
 
2. Methods 
2.2 Search Strategy 
Our bibliographic research was carried out using the following search engines: Google Scholar 
and Pub Med. The search for sources was carried out using the following keywords 
(fibromyalgia, chronic pain, pain modulation, menopause, hormones) with different 
combinations using the Boolean operators AND and OR. The search field comprehended both 
title and abstract and time frame was set on last ten years, while research articles, book chapters 
and reviews were included.  
 
3. Results 
Among all the articles collected (248), those most relevant to the research topic were selected, 
with the following inclusion criteria: title or abstract had to contain both the syndromes in 
comparison, or an element among the following that could underline the overlapping 
symptomatology between the two (hormone related hypothesis, psychological and psycho-
physiological correlations).  
After the excluded articles we had a corpus of thirty-three papers; in addition to the online 
search criteria described above, we also hand cross-referenced the publication list referenced by 
each of the studies we included to ensure that no studies of significance were omitted, including 
also some papers dated to previous years but worthy of consideration. For the present review, 
forty-nine studies were identified through the combined search criteria and found to be eligible 
for inclusion, analysed and divided according to the following criteria, to find the link between 
the two syndromes. In introducing new themes, the number of articles considered will be 
expressed in brackets. 
3.1 Hormone related evidence  
3.1.1 Neuroendocrine hypothesis of FM 
Epidemiological studies reveal a clear prevalence of women in chronic pain syndromes (in both 
intensity and frequency) especially regarding that of musculoskeletal origin, or visceral with an 
autoimmune etiology. Studies carried out on laboratory animals have shown that the modulation 
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of estrogen or androgen levels is able to modify behavioral, hormonal and neuronal responses 
to persistent nociceptive stimuli (Aloisi & Ceccarelli, 2001).  
Recently, hypocortisolism has been reported both in patients who develop disorders due to 
post-traumatic stress and additionally in patients suffering from FM, chronic fatigue syndrome, 
and chronic pelvic pain. The development of hypocortisolism can be due to alterations of the 
hypothalamic-pituitary adrenal axis, due to genetic factors and stress factors, characterized by a 
lower availability of cortisol, and to a greater sensitivity to negative feedback of the axis and the 
bonding of cortisol within target cells (Heim et al., 2000).  In accordance with these hypotheses, 
some studies show a reduction in urinary cortisol using samples of 24-hour urine from FM 
patients, probably due to hypersecretion of corticotropic hormone (CRH) with down regulation 
of CRH receptors in the pituitary gland, to glucocorticoid resistance or variations morphological 
at different axis levels (Dessein et al., 2000). In contrast to these observations, a hyperactivity 
of the HPA axis was observed in FM patients with elevated levels of cortisol, which is also 
associated with the degree or severity of depression; a common symptom in FM (Neeck, 2000). 
Furthermore, the involvement of the HPA axis has been studied to assess the stress levels 
induced by nociceptive stimulation. The results reported that females have corticosterone and 
ACTH levels higher than males and that nociceptive stimulation induces an increase in 
circulating levels of ACTH in females, but not in males; in contrast, corticosterone levels 
measured after nociceptive stimulation did not differ from controls in both genders (Pieretti et 
al., 1996). Since FM syndrome typically occurs in women at the beginning of menopause, an 
estrogen deficiency has been proposed as an associated factor (Waxman & Zatskis, 1986). 
Finally, there are premenopausal women with FM, although there are no significant alterations 
in the levels of estradiol, progesterone or follicle-stimulating hormone (Korszun et al., 2000). 
Abnormalities in corticotropin-releasing hormone profiles can influence the stress response, 
alter the central mechanism of nociception, modify the role of other hormones mediated 
through the HPA axis, and induce hypofunction of the neurotransmitter systems that influence 
mood, motivation and somatic processes like sleep (Neeck & Crofford, 2000). 
3.1.2 Somatotrophic axis 
The HPA axis is closely related to the secretion of the growth hormone (GH), produced by the 
corticotropin release factor (CRF). Numerous studies have shown that people with FM have a 
deficiency in the secretion of growth hormone (GH) and insulin-like growth factor (IGF1). It 
is also known that, GH and IGF-1, play an important role in the regulation of body composition, 
lipid profile, tissue repair, cardiac and nervous function, and bone density (Martinelli et al., 
2008). A significant number of studies indicate that a change in GH levels may increase energy 
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levels, strength, heart and cognitive function, immune response, and psychological well-being. 
It is also believed that over 30% of women with FM have subnormal IGF-1 levels, despite this, 
correlation between the research and the hypothesis has been heavily criticized due to the 
numerous variables in the concerned populations (Shuer, 2003).  
In a double-blind, placebo-controlled study, GH was administered in 25 women who met the 
diagnostic criteria of the American College of Rheumathology for FM. The results showed a 
significant improvement in symptoms and functional capacity in conjunction with an increase 
in IGF-1 levels (Bennett et al., 1998). Other studies have shown a significant decrease in pain 
after 6/12 months of GH treatment in women with FM (Leal-Cerro et al., 2002). 
Another hypothesis concerns a correlation between the HPA function and a reduction of slow-
wave sleep (SWS) in FM. Several studies carried out through polysomnography, document the 
presence of a reduced proportion of slow-wave sleep, REM sleep and total sleep, as well as a 
greater number of prolonged awakenings and an electroencephalographic intrusion pattern of 
alpha waves (waves associated with the awakening reaction) on the delta rhythm (slow waves 
that characterize deep sleep) in subjects with FM when compared to control groups (Roizenblatt 
et al., 2001).  
3.1.3 Effects of androgens (DHEA and DHEAs) 
In women diagnosed with FM, in addition to pain, fatigue and depression, there is evidence of 
hormonal changes that occur with alterations in cortisol and adrenal glands. Furthermore, to 
the role of estrogens and progesterone in the psycho-neuroendocrine modulation, androgens 
play an important role along with that of neuroactive steroids; such as dehydroepiandrosterone 
(DHEA), which represents the main steroid hormone produced by the secretion of adrenal 
glands, also produced in the gonads and the brain, and dehydroepiandosterone sulfate 
(DHEAs); produced almost exclusively by the adrenal cortex. The concentration of these 
hormones is closely related to cognitive functions, immune patterns and the reduction of 
circulating cortisol (Grimaldi et al., 2006). 
Since hormonal alterations are very common in MP and post-menopausal women, it could 
affect the symptoms of FM (Abeles et al., 2007; Gupta & Silman, 2004; Pamuk et al., 2009). 
Moreover, women with FM which present low levels of androgens, report changes in pain 
perception and increased muscle fatigue (Bradley et al., 2000; Finckh et al., 2005). 
3.1.4 Hypothalamic-pituitary-gonadal axis and pain 
The observation of a worsening of pain with menopause, when the levels of estrogens are low, 
suggested an association of these hormones with analgesia; on the other hand, even with regard 
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to testosterone, the sensitivity levels in certain conditions of pain in men has led to hypothesize 
its analgesic role (Berkley & Holdkroft, 1999). 
In fact, besides the similarity on the symptomatology, there are other observations which may 
suggest a link between FM and disorders in ovarian function. In fertile women, the fluctuations 
of the ovarian hormones during the menstrual cycle seem to be associated with a mild to 
moderate effect on pain response; one of key features of FM (Martin, 2009). One study 
demonstrates that in most FM patients a worsening of symptoms is observed during the 
premenstrual period, i.e, in one Ovarian cycle phase with low estradiol levels (Ostensen et al., 
1997). Some other researchers have also observed an increase and worsening of generalized 
pain, fatigue and other symptoms in women with FM during post-menopause. In the same 
study, the authors also identified the incidence of early menopause as significantly higher in 
patients with FM compared to patients with rheumatoid arthritis and healthy controls (Pamuk 
et al., 2009). 
Although estrogens play a fundamental role in the modulation of pain, and FM patients are 
mainly women, their role is not yet fully understood. These hormones seem to be 
pronociceptive in certain experimental and antinociceptive concentrations in others (Aloisi et 
al., 2007; Fillingim & Maixner, 1995). Some studies reported changes in pain that post-
menopausal women have experienced between the pre-menopausal periods and post-
menopause. To this end, ad hoc questionnaires were used to study the socio-demographic data, 
clinical history, levels of subjective pain and pain familiarity. Furthermore, it has been observed 
that the attention paid to pain has produced a significant inhibition of wind-up phenomenon in 
women with FM compared to healthy men or women (Staud et al., 2003). It has also been 
observed that the symptoms of FM are aggravated during other events related to sex hormones, 
such as pregnancy or postpartum (Ostensen et al., 1997; Pamuk & Cakir, 2005).  
As for the relationship between FM and MP, the influence of the age of onset of climacteric 
syndrome on pain and sensitivity was observed: in fact, sensitivity to pain would be higher in 
patients with FM with early onset of MP than in those in which it occurred later. These results 
document how a sharp decline or reduction in ovarian hormones can affect syndromes of 
chronic musculoskeletal pain, such as FM (Meriggiola, 2012). 
3.1.5 Inflammatory cytokines in FM and influence of aging and menopause on FM 
Several studies have recognized potential abnormalities in the inflammatory system that can 
contribute to the perpetuation of the symptoms of FM. The imbalance of inflammatory pro and 
anti-cytokines is considered a possible cause of induction and maintenance of pain in FM 
(Üçeyler et al., 2001).  
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In fact, many researchers have found high levels of circulating inflammatory cytokines and 
chemokines in FM patients; in particular, IL-6, IL-8, IL-10 and TNF-α  (Interleukin-6, 
Interleukin-8, Interleukin-10, Tumor necrosis factor) (Bazzichi et al., 2007; Dowlati et al., 2010; 
Miller et al., 2009; Wang et al., 2008). The production or the increase of inflammatory cytokines 
in the animal model itself seems to represent an interesting reference to the human condition. 
When the laboratory mice are stimulated with lipopolysaccharide (LPS) injections in order to 
induce an increased interleukin-1 (il-1), they show the typical "disease behavior" which is 
characterized by non-specific infectious symptoms, including weakness, malaise, listlessness, 
hypersomnia and loss of interest in social activities. In the animal model, this behavior is 
protective, since the animal uses less energy in daily activities, but remains inactive in an attempt 
to fight the infection (Parnet et al., 2002). The syndromic constellation of women with FM 
appears similar to the "disease behavior" expressed by mice; but while the animals are able to 
regenerate following the LPS injection-induced transient change, women with FM remain in the 
pain behavior state (Shuer, 2003). 
The differences between cytokine and chemokine levels underlying FM syndrome are taken into 
consideration also from the point of view of human aging, as the prevalence of the syndrome 
increases in older populations (Wolfe et al., 1995) and inflammatory responses change 
depending on the normal process of aging (Üçeyler et al., 2011; Wang et al., 2008). Several 
studies suggest that IL-6, IL-8 and TNF-α increase with age (Burns & Goodwin, 1997; Kiecolt-
Glaser et al., 2003) and direct the inflammatory response, particularly if accompanied by stressful 
life situations (Kiecolt-Glaser et al, 2003). Other studies have hypothesized that the onset of 
MP may be the basis for age-related cytokine changes in women with FM. Indeed, some 
researchers have observed an increase in the rate of MP and hysterectomies in women with FM; 
others, have reported that the symptomatology of FM can begin or worsen with the onset of 
MP itself (Buskila et al., 2007). 
3.2 Psychological and psychophysiological correlates 
Several of the analyzed studies suggest that FM is associated with a broad spectrum of clinical 
manifestations and comorbidities, such as altered moods and anxiety disorders. These 
conditions also share some neurochemical dysfunctions, alterations of the central nervous 
system, and alteration of the HPA axis (Bernik et al., 2013). Furthermore, FM is also associated 
with fatigue, muscle stiffness, headache, sleep disorders, irritable bowel syndrome, cognitive 
disorders with reduction in concentration and memory loss (Marangell et al., 2011; Theadom & 
Cropley, 2008).  
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Major Depression Disorder (MDD) has been studied with particular attention in subjects with 
FM, considering that it has a negative impact on pain tolerance and on the patient's socio-
functionality. In addition, the diagnosis of MDD is particularly complex in the FM patient due 
to the symptomatological similarities between the two (Okifuji et al., 2000). In the context of 
the monoaminergic hypothesis of depression, the mood disorder would be caused by a lack of 
neurotransmitters at the synaptic level; in particular, regarding deficits of serotonin (5HT), 
noradrenaline (NA) and dopamine (DA) (Robinson et al., 2013). As we know, at the base of 
FM, alteration in pain and mood modulation systems were hypothesized as common 
pathogenetic mechanisms (Stahl & Briley, 2004). Furthermore, serotonin and noradrenaline 
originate in the raphe nuclei and project the information to the spinal marrow and forebrain, 
exerting influence both on the processing of pain and on mood (Arnold et al., 2006; Porreca et 
al., 2002; Suzuki et al., 2004, 2005).  
Regarding this, some studies have tried to examine the association between the state of 
depression and the risk of developing anxiety in a sample of middle-aged Australian women. 
Findings suggested that middle-aged women in perimenopause are more likely to develop 
symptoms of depression; postmenopausal women, on the other hand, are more likely to develop 
anxious symptoms. Ultimately, both perimenopause and post-menopause conditions seem to 
increase the risk of anxiety or depression (De Kruif et al., 2016). 
3.2.1 Correlations between sexual hormones and memory function 
Based on the analysis of scientific studies, a hypothesis has emerged regarding the loss of 
estrogen, which is typical in MP, which could mediate the existing bond between memory and 
sex hormones in women with FM. 
Estrogen loss is also linked to the risk of developing depression or anxiety, as well as 
osteoporotic, cerebrovascular and cardiovascular disorders (Buckler, 2005).  Moreover, a study 
performed by Armeni and colleagues aimed to assess the association between memory and 
serum levels of sex hormones (Armeni et al., 2018). The results showed that a higher frequency 
of cognitive symptoms (such as short-term memory problems and difficulty in remembering 
words or numbers) have been found during the menopausal transition (Greendale et al., 2011). 
Similarly, women with FM complain of numerous cognitive symptoms similar to those 
experienced by women in MP, also presenting difficulties with attention and concentration, 
working and episodic memory and verbal fluency (Shuer, 2003). Furthermore, the alteration of 
the gray matter in the frontal regions, whose task is that of regulating the processes of planning, 
as well as the control and coordination of the cognitive system, seems to play an important role 
in the neuropsychological aspects of the FM patient (Ceko et al., 2012; Luerding et al., 2008). 
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3.2.1 Morphological alterations in FM 
Different pain conditions appear to be associated with different patterns of cerebral 
morphology alteration. Even today, it remains unclear whether the pain duration causes changes 
in the brain or if a certain cerebral morphology makes the subject more prone to chronic pain 
and pain amplification. Studies conducted using functional neuroimaging techniques have 
shown that in patients with FM, there is an alteration in the processing of pain, as well as 
anatomical and neurochemical differences compared to healthy control groups (Arnoldi et al., 
2011; Ceko et al., 2012). Furthermore, patients with FM appear to have more brain activity in 
response to pressure and thermal stimuli in numerous brain areas: specifically, in regions 
involved in sensory and discriminative processes, such as the primary and secondary 
somatosensory cortex and in limbic systems. In FM, several anatomical sites are involved; in 
particular, the orbital-frontal cortex, the lateral dorsal prefrontal cortex (Apkarian et al., 2004) 
and the insular cortex (Kuchinad et al., 2007; Schmidit-Wilcke et al., 2005, 2008). 
3.2.2 Neurotrophic hypotesis of FM 
Many researchers believe that at the base of FM etiology there is the involvement of the central 
nervous system. Neuroplasticity allows the body to change and adapt to environmental demands 
mediating the synthesis of neurons in painful syndromes such as migraine headaches, 
rheumatoid arthritis and FM, as well as the degeneration of neurons caused by inflammatory 
factors (McEwen & Gianaros, 2011). The transformation that the hippocampus and amygdala 
undergo in the event of chronic stress is the classic example of it; the hippocampus which is 
also involved in the management of emotions, language and motivation, experiences a decrease 
in volume, its neurons lose their dendritic branches and glucocorticoid receptors diminish, 
preventing the hippocampus from turning off the stress reaction.  
The neurotrophic hypothesis confirms that the hippocampal hypotrophy is a consequence of 
intense activity of the HPA axis induced by the presence of chronic stress, which determines a 
disproportionate increase in levels of cortisol, which stimulates the activity of both particular 
pro-inflammatory cytokines and of glutamate, eliciting the triggering of neurotoxicity 
mechanisms. This may cause a progressive degeneration of neuronal cells, particularly in the 
hippocampus (McEwen, 1999). In line with this hypothesis, further studies show a reduction in 
volume of some cerebral areas that interest, first of all, the hippocampus and also the prefrontal 
cortex and the nucleus accumbens (Palma & Brugnoli, 2007).  
Finally, a very important role is played by the brain neurotrophic factor (BDNF) which is part 
of the family of neuronal growth factors. It is involved in synaptic plasticity of the central and 
peripheral nervous systems. Emerging data in literature suggest that it has a modulatory role on 
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nociceptive sensory inputs, both at a central and a peripheral level and is thought to be involved 
in some painful conditions such as neuropathic and inflammatory pain. In fact, some studies 
have confirmed a variation of the baseline levels of BDNF in FM compared to healthy controls 
(Laske et al., 2007). 
 
4. Discussion and conclusions  
To date, the mechanisms underlying the etiopathogenesis of FM have not been completely 
clarified. However, in light of recent scientific evidence, FM can be defined as a part of a broader 
spectrum, a continuum, which includes several factors involved in the underlying 
pathophysiological mechanism such as genetic factors, abnormalities of the autonomic and 
neuroendocrine nervous system, anomalies of the central nervous system, and environmental 
triggers. Moreover, the combination of several potentially responsible factors opens interesting 
scenarios regarding the study of the endocrine aspect and, specifically, of MP; sometimes 
considered as a cause and as a symptomatic or therapeutic target. The analyzed studies showed 
that the decreasing physiological hormone levels that alter brain neurotransmission during MP 
causes similar symptoms in FM, to the point that FM may be conceptualized as a part of the 
climacteric syndrome or that the two syndromes may be superimposed. To date, the 
neuroendocrine hypothesis and the neurotrophic hypothesis are the most accredited regarding 
the interdependence of the two syndromes; as estrogen declines, progesterones and androgens 
inevitably have an impact both on the biological profile, psychological and behavioral of women 
with FM, influencing them to be more responsive to stressful events and likely to develop 
symptoms such as depression or anxiety. Ultimately, since FM has a 97% rate of female onset, 
the researchers speculate that the hormonal sphere is capable of profoundly affecting also the 
patient’s mood. Furthermore, polysomnography studies show that the variation in hormones 
levels can interfere with sleep quality and cognitive function. 
This review suffers from several limitations and weaknesses. The major challenges encountered 
were the following: first of all, the fact of not having used a purely psychological bibliographic 
search database has limited the material available for the analysis with this aspect. Secondly, not 
many experimental studies have emerged from the research but rather dissertations on the 
subject were found which made the critical exposition of the results quite complex. Finally, we 
observed a lack of scientific evidence about psychological interrelation between the two 
syndromes, requiring more in-depth research. 
In conclusion, the current review has confirmed an overlap in symptom manifestation of the 
two syndromes (FM and MP). Despite an increasing number of studies have highlighted the 
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interdependence between FM and MP, little importance has been given so far in the clinical 
practice to the investigation of the two syndromes when coexisting. For future research and in 
light with the new evidences provided by the recent literature, it is suggested to continue the 
research on the present topic by focusing on psychological and biopsychosocial perspective 
often neglected in the analysed literature. It would be important to understand the benefit of 
the symptomatologic improvement of one of the two syndromes on the other, both from a 
psychological and medical point of view, and to provide a reassurance to the patient who finds 
herself experiencing a huge corollary of symptoms at the same time. 
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